Biomea Fusion price target lowered to $9 from $10 at Oppenheimer

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Biomea Fusion (BMEA) to $9 from $10 and keeps an Outperform rating on the shares. The firm is updating its model following the company’s Q2 results and the management’s latest cash burn guidance, noting that its cash position should allow for sustained operations into the second half of FY26, the analyst tells investors in a research note.